FDA Approves ALS Stem Cell Trial at University of Michigan

A new approval from the U.S. Food and Drug Administration paves the way for the University of Michigan to become the second site of a trial using stem cell injections to treat sufferers of Lou Gehrig’s Disease. The Phase II trial will determine the safety of the injections, which are delivered directly to the patients’ spinal cords. Click here to read the full story.